E. Koenig

机构：AbbVie (United States)

发表论文 26 篇 · 总被引 722 次 · h-index 8

代表论文

• Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 (2019 · Movement Disorders · 被引 200)
• Safety, tolerability, and pharmacokinetics of casimersen in patients with D uchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial (2021 · Muscle & Nerve · 被引 152)
• Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial (2021 · Nucleic Acid Therapeutics · 被引 128)
• Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial (2021 · Journal of Neuromuscular Diseases · 被引 119)
• The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy (2021 · Acta Neuropathologica Communications · 被引 37)
• Isolation and identification of the platelet aggregation inhibitor present in the onion,Allium cepa (1972 · FEBS Letters · 被引 32)